Kiniksa Pharmaceuticals, Ltd. – NASDAQ:KNSA

Add to watchlist

$33

+12.98

+64.92%

Market closed

Open in 2 days

-5.66%

month

-5.66%

quarter

+7.81%

year

Market Cap	1.46B
Enterprise value	632.20M

P/E	4.03
EV/Sales	2.87
EV/EBITDA	43.06
Price/Sales	3.40
Price/Book	1.89
PEG ratio	0.01
EPS	0.11

Revenue	301.77M
EBITDA	-29.84M
Income	8.65M
Revenue Q/Q	65.18%
Revenue Y/Y	27.68%

Profit margin	83.28%
Oper. margin	4.44%
Gross margin	91.27%
EBIT margin	4.44%
EBITDA margin	-9.89%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Kiniksa Pharmaceuticals, Ltd. Stock Forecast

M Q Y

Last Year

$37.5

Potential upside: 13.63%

Analysts Price target
Financials & Ratios estimates

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA): Profit margin
Jun 2023	71.47M	14.97M	20.95%
Sep 2023	67.04M	-13.85M	-20.66%
Dec 2023	83.39M	25.23M	30.26%
Mar 2024	79.85M	-17.70M	-22.17%

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA): Earnings per share (EPS)
2024-02-28	-0.11	0.04
2024-04-23	-0.14	-0.25

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA): Debt to assets
Jun 2023	484332000	72.67M	15.01%
Sep 2023	483063000	77.93M	16.13%
Dec 2023	526322000	87.48M	16.62%
Mar 2024	519673000	87.77M	16.89%

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA): Cash Flow
Jun 2023	-3.74M	35.53M	158K
Sep 2023	16.98M	-12.27M	552K
Dec 2023	4.32M	-14.89M	695K
Mar 2024	3.98M	25.52M	3.61M

Kiniksa Pharmaceuticals, Ltd. alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Kiniksa Pharmaceuticals, Ltd.
Employees

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA): Employee count
Aug 2023	220
Sep 2023	220
Oct 2023	220
Nov 2023	220
Dec 2023	220
Jan 2024	220
Feb 2024	220
Mar 2024	297
Apr 2024	297
May 2024	297
Jun 2024	297
Jul 2024	297

Kiniksa Pharmaceuticals, Ltd.
Hedge Funds Holdings Q1 2023

18.42% -24.50%

of KNSA is owned by hedge funds

76 -47

hedge funds hold KNSA stock

12.96M -17.30M

shares is hold by hedge funds

KNSA hedge funds holdings changes

Kiniksa Pharmaceuticals, Ltd.
Insider Trading

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	28670
Feb 2024	0	15282
Mar 2024	0	113028
Sep 2024	0	146698
Oct 2024	0	17000
Nov 2024	0	106570
Dec 2024	0	37921

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	9 Dec 2024	RAGOSA MARK officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Class A Ordinary Share	18,860	$11.1	$209,346
Sale	9 Dec 2024	RAGOSA MARK officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Class A Ordinary Share	18,860	$21.38	$403,227
Option	9 Dec 2024	RAGOSA MARK officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Share Option	18,860	$11.1	$209,346
Option	6 Dec 2024	RAGOSA MARK officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Class A Ordinary Share	2,406	$10.76	$25,889
Option	6 Dec 2024	RAGOSA MARK officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Share Option	2,406	$10.76	$25,889
Sale	6 Dec 2024	RAGOSA MARK officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Class A Ordinary Share	8,969	$21.27	$190,771
Option	5 Dec 2024	RAGOSA MARK officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Share Option	1,123	$10.76	$12,083
Option	5 Dec 2024	RAGOSA MARK officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Class A Ordinary Share	1,123	$10.76	$12,083
Sale	5 Dec 2024	RAGOSA MARK officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Class A Ordinary Share	1,123	$21.25	$23,864
Option	4 Dec 2024	RAGOSA MARK officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Share Option	5,024	$10.76	$54,058

KNSA insider trading transactions

Kiniksa Pharmaceuticals, Ltd.
Patents

Status	Patent	Filling date	Issue date
Application	Application PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME Filling date: 17 Dec 2021 Issue date: 8 Sep 2022	17 Dec 2021	8 Sep 2022
Application	Application TREATMENT OF CANCERS WITH GM-CSF ANTAGONISTS Filling date: 26 Oct 2021 Issue date: 16 Jun 2022	26 Oct 2021	16 Jun 2022
Grant	Grant Utility: Treatment of cytokine release syndrome with GM-CSF antagonists Filling date: 19 May 2021 Issue date: 10 May 2022	19 May 2021	10 May 2022
Application	Application Stable Anti-OSMR Antibody Formulation Filling date: 8 Sep 2021 Issue date: 3 Mar 2022	8 Sep 2021	3 Mar 2022
Application	Application ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS Filling date: 3 Sep 2021 Issue date: 24 Feb 2022	3 Sep 2021	24 Feb 2022
Grant	Grant Utility: Stable anti-OSMR antibody formulation Filling date: 26 Aug 2019 Issue date: 12 Oct 2021	26 Aug 2019	12 Oct 2021
Application	Application TREATMENT OF CYTOKINE RELEASE SYNDROME WITH GM-CSF ANTAGONISTS Filling date: 19 May 2021 Issue date: 16 Sep 2021	19 May 2021	16 Sep 2021
Application	Application TREATMENT OF CYTOKINE RELEASE SYNDROME WITH GM-CSF ANTAGONISTS Filling date: 15 Mar 2021 Issue date: 16 Sep 2021	15 Mar 2021	16 Sep 2021
Application	Application TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRB ANTIBODY Filling date: 25 Apr 2019 Issue date: 25 Feb 2021	25 Apr 2019	25 Feb 2021
Application	Application Stable Anti-OSMR Antibody Formulation Filling date: 26 Aug 2019 Issue date: 27 Feb 2020	26 Aug 2019	27 Feb 2020

KNSA patents

Kiniksa Pharmaceuticals, Ltd.
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 23 Apr 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 31 Oct 2023	Q3 2023 Earnings Call Transcript
Q2 2023 25 Jul 2023	Q2 2023 Earnings Call Transcript

KNSA earnings call transcripts

Kiniksa Pharmaceuticals, Ltd.
Executives

Insider	Age	Since	Compensation
Mr. Sanj K. Patel (1970) Chief Executive Officer & Chairman	55		$1,430,000

Kiniksa Pharmaceuticals, Ltd.
Latest News

Tuesday, 26 November 2024
16:01	Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference	globenewswire.com
Tuesday, 12 November 2024
16:01	Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference	globenewswire.com
Tuesday, 29 October 2024
11:45	Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript	seekingalpha.com
09:46	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
07:30	Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution	globenewswire.com
Tuesday, 22 October 2024
16:01	Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024	globenewswire.com
Friday, 11 October 2024
09:51	What Makes Kiniksa Pharmaceuticals (KNSA) a Good Fit for 'Trend Investing'	zacks.com
Wednesday, 9 October 2024
10:56	Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet	zacks.com
Friday, 20 September 2024
09:56	Kiniksa Pharmaceuticals (KNSA) is on the Move, Here's Why the Trend Could be Sustainable	zacks.com
Wednesday, 28 August 2024
16:01	Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference	globenewswire.com
Monday, 5 August 2024
11:01	Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade	zacks.com
Friday, 2 August 2024
08:22	5 Stocks With Recent Price Strength in a Volatile Market	zacks.com
Thursday, 1 August 2024
11:15	Best Momentum Stocks to Buy for August 1st	zacks.com
08:21	New Strong Buy Stocks for August 1st	zacks.com
Friday, 26 July 2024
13:01	Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know	zacks.com
09:51	Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why	zacks.com
Wednesday, 24 July 2024
05:38	Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat	seekingalpha.com
Tuesday, 23 July 2024
09:35	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
Tuesday, 16 July 2024
16:01	Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024	globenewswire.com
Tuesday, 9 July 2024
08:00	Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren's Disease	globenewswire.com
Monday, 17 June 2024
08:30	Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative	globenewswire.com
Tuesday, 4 June 2024
16:01	Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference	globenewswire.com
Tuesday, 7 May 2024
16:01	Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference	globenewswire.com
Wednesday, 24 April 2024
13:34	Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape	seekingalpha.com
Tuesday, 23 April 2024
13:59	Kiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call Transcript	seekingalpha.com
09:41	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Tuesday, 16 April 2024
16:01	Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024	GlobeNewsWire
Friday, 1 March 2024
10:56	Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect?	Zacks Investment Research
Thursday, 29 February 2024
13:01	Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd.	Zacks Investment Research
07:51	New Strong Buy Stocks for February 29th	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 16 Jun 2025

Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast
Seeking Alpha 24 Apr 2024

Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Seeking Alpha 5 Jan 2024

Kiniksa Pharmaceuticals: Early 2024 Corporate Update A Mixed Bag
Seeking Alpha 3 Nov 2023

Kiniksa Pharmaceuticals: Arcalyst Performs While KPL-404 Advances Toward Early 2024 Readout
Seeking Alpha 27 Jul 2023

Kiniksa Pharmaceuticals: Arcalyst's Growth Picks Up
Seeking Alpha 19 Jul 2023

Kiniksa Pharmaceuticals: Autoimmune Therapy Offers Attractive Prospects At Current Price
Seeking Alpha 19 Feb 2023

Kiniksa: Steady Progress With Arcalyst, But Still Pretty Unexciting
Seeking Alpha 7 Mar 2022

Week In Review: Adagene Forms $2.5-Billion, Four-Drug Partnership With Sanofi
Seeking Alpha 28 Feb 2022

Week In Review: Huadong Pharma Enters $662 Million Deal For 2 Kiniksa Anti-Inflammatory Drugs
Seeking Alpha 25 Nov 2021

Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel

Frequently Asked Questions (FAQ)

What's the price of Kiniksa Pharmaceuticals, Ltd. stock today?

One share of Kiniksa Pharmaceuticals, Ltd. stock can currently be purchased for approximately $33.
When is Kiniksa Pharmaceuticals, Ltd.'s next earnings date?

Unfortunately, Kiniksa Pharmaceuticals, Ltd.'s (KNSA) next earnings date is currently unknown.
Does Kiniksa Pharmaceuticals, Ltd. pay dividends?

No, Kiniksa Pharmaceuticals, Ltd. does not pay dividends.
How much money does Kiniksa Pharmaceuticals, Ltd. make?

Kiniksa Pharmaceuticals, Ltd. has a market capitalization of 1.46B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22.74% to 270.26M US dollars. Kiniksa Pharmaceuticals, Ltd. earned 14.08M US dollars in net income (profit) last year or -$0.25 on an earnings per share basis.
What is Kiniksa Pharmaceuticals, Ltd.'s stock symbol?

Kiniksa Pharmaceuticals, Ltd. is traded on the NASDAQ under the ticker symbol "KNSA".
What is Kiniksa Pharmaceuticals, Ltd.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Kiniksa Pharmaceuticals, Ltd.?

Shares of Kiniksa Pharmaceuticals, Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Kiniksa Pharmaceuticals, Ltd.'s key executives?
Kiniksa Pharmaceuticals, Ltd.'s management team includes the following people:
- Mr. Sanj K. Patel Chief Executive Officer & Chairman(age: 55, pay: $1,430,000)
How many employees does Kiniksa Pharmaceuticals, Ltd. have?

As Jul 2024, Kiniksa Pharmaceuticals, Ltd. employs 297 workers.
When Kiniksa Pharmaceuticals, Ltd. went public?

Kiniksa Pharmaceuticals, Ltd. is publicly traded company for more then 7 years since IPO on 25 May 2018.
What is Kiniksa Pharmaceuticals, Ltd.'s official website?

The official website for Kiniksa Pharmaceuticals, Ltd. is kiniksa.com.
How can i contact Kiniksa Pharmaceuticals, Ltd.?

Kiniksa Pharmaceuticals, Ltd. can be reached via phone at +7 814399100.
What is Kiniksa Pharmaceuticals, Ltd. stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Kiniksa Pharmaceuticals, Ltd. in the last 12 months, the avarage price target is $37.5. The average price target represents a 13.63% change from the last price of $33.

Kiniksa Pharmaceuticals, Ltd.

kiniksa.com

Exchange:

NASDAQ

Full time employees:

297

Industry:

Biotechnology

Sector:

Healthcare

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

+7 814399100

Clarendon House
Hamilton, HM 11

CIK: 0001730430
ISIN: BMG5269C1010
CUSIP: G5269C101